Patents by Inventor Ralph Strecker

Ralph Strecker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8208987
    Abstract: A method for quantifying the uptake of at least one radiotracer in a body region of a patient of interest to a positron emission tomography measurement is disclosed. In at least one embodiment of the method, the uptake of the radiotracer in the body region of the patient of interest to the positron emission tomography measurement is quantified taking into account at least one permeability information item relating to the permeability of at least one blood vessel of the patient, in particular in the body region of interest.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: June 26, 2012
    Assignee: Siemens Aktiengesellschaft
    Inventors: Arne Hengerer, Ralph Strecker
  • Patent number: 8195275
    Abstract: A system and method of evaluating the effectiveness of antiangionetic therapy is described. A patient or test animal is treated with an antiangionetic substance. Magnetic resonance imaging data is obtained prior to and subsequent to the treatment. The parameters of the imaging process are configured so that, by administering a intravascular contrast agent, the relative size of the microvascular and the total vascular volumes in a region of interest may be obtained, so as to form a vascular size index. The value of the vascular size index and other pharmacokinetic data obtained by the administration of a diffusible contrast agent are used to assess the efficacy of the treatment or the antiangionetic substance being studied.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: June 5, 2012
    Assignee: Siemens Aktiengesellschaft
    Inventors: Stefan Zwick, Ralph Strecker, Fabian Kiessling, Arne Hengerer, Sebastian Schmidt
  • Publication number: 20100254584
    Abstract: A method for assessing a tumor's response to therapy, includes providing images of a first study of a patient and images of a second study of the patient, the second study occurring after the first study and after the patient undergoes therapy to treat a tumor, each study comprising first and second types of functional magnetic resonance (fMR) images, performing a first registration in which the images within each study are registered, performing a second registration in which reference images from both studies are co-registered, segmenting the tumor in an image of each of the second registered studies; and determining that first and second fMR measure differences exist between the segmented tumor's of the first and second studies, the first fMR measure difference being obtained from the first type of fMR images, the second fMR measure difference being obtained from the second type of fMR images.
    Type: Application
    Filed: March 31, 2010
    Publication date: October 7, 2010
    Applicant: Siemens Corporation
    Inventors: Mehmet Akif Gulsun, Ralph Strecker, Glenn A. Meredith, Ihab R. Kamel
  • Publication number: 20090117044
    Abstract: A method for quantifying the uptake of at least one radiotracer in a body region of a patient of interest to a positron emission tomography measurement is disclosed. In at least one embodiment of the method, the uptake of the radiotracer in the body region of the patient of interest to the positron emission tomography measurement is quantified taking into account at least one permeability information item relating to the permeability of at least one blood vessel of the patient, in particular in the body region of interest.
    Type: Application
    Filed: August 20, 2008
    Publication date: May 7, 2009
    Inventors: Arne Hengerer, Ralph Strecker
  • Publication number: 20090062630
    Abstract: A sensor is disclosed for permitting detection of a substance in the body of a living being. In at least one embodiment, the sensor includes probe molecules, for binding the substance that is to be detected, and marking elements designed in such a way that the binding of the probe molecules to the substance to be detected is detectable by way of an imaging modality. For example, antigens or pathogens that are present only in a low concentration can be detected.
    Type: Application
    Filed: August 15, 2008
    Publication date: March 5, 2009
    Inventors: Arne Hengerer, Robert Krieg, Sebastian Schmidt, Ralph Strecker
  • Publication number: 20080294035
    Abstract: A system and method of evaluating the effectiveness of antiangionetic therapy is described. A patient or test animal is treated with an antiangionetic substance. Magnetic resonance imaging data is obtained prior to and subsequent to the treatment. The parameters of the imaging process are configured so that, by administering a intravascular contrast agent, the relative size of the microvascular and the total vascular volumes in a region of interest may be obtained, so as to form a vascular size index. The value of the vascular size index and other pharmacokinetic data obtained by the administration of a diffusible contrast agent are used to assess the efficacy of the treatment or the antiangionetic substance being studied.
    Type: Application
    Filed: May 21, 2008
    Publication date: November 27, 2008
    Inventors: Stefan Zwick, Ralph Strecker, Fabian Kiessling, Arne Hengerer, Sebastian Schmidt